Overview
Cerebrolysin is genuinely interesting editorially because it is not a single compound — it is a defined mixture of low-molecular-weight neuroactive peptides and free amino acids enzymatically extracted from young porcine brain tissue, manufactured by the Austrian company EVER Pharma. It has been clinically used for over 30 years across Europe, Russia, China, and parts of Latin America for acute ischemic stroke, vascular and Alzheimer's-type dementias, and traumatic brain injury — with several adequately-sized RCTs (notably CASTA in stroke and several Alzheimer's trials). It is NOT FDA-approved in the United States. The multi-component nature makes it harder to characterize than a single-molecule drug — different batches are standardized but the active component(s) are not isolated — which is itself an unusual editorial framing in a 'peptide' library.
Mechanism
Proposed multi-component mechanism: low-molecular-weight peptides with claimed BBB penetration that may mimic endogenous neurotrophic-factor signaling (BDNF/NGF/GDNF-like effects), modulation of glutamate excitotoxicity, anti-apoptotic effects in neuronal cultures, and amino acid contributions to neurotransmitter substrate pools. The relative contribution of each fraction to clinical effect is not well characterized — this is a methodological caution, not a dismissal.
Evidence by indication
We classify each indication separately. The same peptide can be Tier 1 for one use and Tier 4 for another. Tiers reflect the published literature, not the strength of community framing.
Acute ischemic stroke (in approved markets)
CASTA trial (Heiss et al., Stroke 2012, n=1,070) — large multinational placebo-controlled RCT — showed Cerebrolysin did NOT reach the primary efficacy endpoint at the population level, but pre-specified subgroup analyses suggested benefit in patients with moderate-to-severe stroke. Subsequent trials and meta-analyses are mixed. Tier 2 (and only that) in approved-market clinical practice; arguably Tier 3 by Western evidence-base standards alone.
Vascular dementia / mild-to-moderate Alzheimer's disease
Multiple RCTs (Panisset 2002, Ruether 2001, Alvarez 2011) and Cochrane reviews show modest cognitive benefits in vascular dementia and mild-to-moderate Alzheimer's. Effect sizes are modest, methodological quality varies, and Cochrane authors have noted heterogeneity. Tier 2.
Traumatic brain injury (moderate-severe)
CAPTAIN trial program in moderate-to-severe TBI (Muresanu et al.) reported improvements in functional recovery measures. Approved in several jurisdictions for TBI use. Tier 2 with caution; the population-level effect sizes are modest.
Off-label nootropic / cognitive enhancement in healthy adults
Community use as a generic nootropic in healthy adults has no controlled-trial support — all approved-indication trials are in patient populations with stroke, dementia, or TBI. Mechanism-as-evidence does not justify population-level extrapolation.
No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.
Pediatric autism / developmental disorders
Some Russian and Eastern European clinical use in pediatric developmental disorders. Limited high-quality controlled trial evidence. Pediatric off-label use in any context should be approached with extra caution.
No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.
Studied dose ranges
The ranges below come from published trial protocols where available, and from documented self-experimenter consensus where the literature does not include human dose-finding work. The notes flag which is which.
Standardized clinical product is supplied as 215.2 mg/mL solution; typical adult dose is 5–10 mL IM (~1–2 g of standardized peptide concentrate) or 10–50 mL slow IV (up to ~10 g) per day. Note unit math: 1 g = 1,000,000 mcg. This is supplement-scale dosing of a complex mixture, not a microgram-dose peptide.
Contraindications
- Severe renal insufficiency (manufacturer warning)
- Pregnancy and breastfeeding (limited safety data)
- Active epilepsy or status epilepticus (rare reports of seizure precipitation; manufacturer warning)
- Known hypersensitivity to porcine proteins or formulation excipients
- Concurrent use with antidepressants/MAOIs requires dose reduction per manufacturer guidance
Reported side effects
- Injection-site discomfort
- Sensation of heat, sweating, dizziness — particularly with rapid IV infusion
- Headache
- Nausea
- Rare: hypersensitivity reactions to porcine-derived components
- Rare: seizure precipitation (manufacturer flag)
- Generally favorable safety profile across decades of approved-market use
Reconstitution & storage
Cerebrolysin is supplied by EVER Pharma as a sterile standardized solution (215.2 mg/mL) in pre-filled vials and ampoules — not patient-reconstituted. IV infusion is diluted in normal saline or 5% dextrose per labeling. IM administration is direct from the vial. This is a manufacturer-controlled product with batch-specific standardization, NOT a research-vendor lyophilized powder.
Storage. Refrigerate or store below 25 °C per label, protect from light. Once opened, use promptly per labeling.
Open the peptide calculator → to compute exact draw volumes for your specific vial and BAC water choice.
Editorial note
DRAFT — pending Wayne's review. Cerebrolysin is editorially distinctive in this library because it is the only multi-peptide mixture rather than a single compound — that's worth surfacing. Clinically it sits in the awkward middle: meaningful Tier 2 evidence in approved markets (stroke, dementia, TBI) but with a primary-endpoint-negative landmark trial (CASTA), modest effect sizes, and significant heterogeneity across the trial base. Off-label nootropic use in healthy adults is firmly Tier 3. Be honest about the negative CASTA primary endpoint — most consumer write-ups omit it.
Citations
- [1]Cerebrolysin in Patients with Acute Ischemic Stroke in Asia: Results of a Double-Blind, Placebo-Controlled Randomized Trial (CASTA)Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; CASTA Investigators. · Stroke · 2012 · PMID 22308253Largest placebo-controlled stroke RCT — primary endpoint negative, subgroup signals positive. The honest anchor for the Tier 2 stroke indication.View source
- [2]Cerebrolysin for Alzheimer's disease (Cochrane Review)Gauthier S, Proaño JV, Jia J, Froelich L, Vester JC, Doppler E. · Cochrane Database of Systematic Reviews · 2015 · PMID 21275064Cochrane systematic review supporting modest Tier 2 benefit in Alzheimer's-type dementia.View source
- [3]Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter TrialMuresanu DF, Heiss WD, Hoemberg V, et al. · Stroke · 2016 · PMID 31957550Multicenter functional-recovery trial supporting Tier 2 framing for stroke and informing TBI program design.View source